Novel p62-based treatment accelerates wound healing and
reduces complications
BOSTON, June 27,
2024 /PRNewswire/ -- CureLab Oncology, a
clinical-stage biotech company, has filed a patent application with
worldwide potential for a revolutionary wound-healing therapy
based on its p62/SQSTM1 DNA plasmid. This innovative approach,
leveraging CureLab's chronic inflammation therapeutic, Elenagen™,
addresses a critical unmet need in the treatment of both acute and
chronic wounds. The therapy offers the potential to significantly
improve patient outcomes, reduce healthcare costs, and transform
the standard of care in this field.
The patented therapy leverages the unique properties of the p62
plasmid to accelerate the natural healing process, reduce
inflammation, and prevent complications such as sepsis, infection,
tissue necrosis, and scarring. Preclinical studies in animal models
have demonstrated the therapy's effectiveness in a variety of wound
types, including cuts, burns, diabetic ulcers, and pressure
sores.
"This patent application is a major milestone for CureLab
Oncology and underscores our commitment to developing innovative
therapies that address significant medical challenges," said
Alexander Shneider, Ph.D., CEO of
CureLab Oncology. "Chronic and acute wounds affect millions of
people worldwide, and our p62-based therapy has the potential to
revolutionize how we treat these debilitating conditions."
The global wound care market is projected to reach USD 37.08 billion by 2032, growing at a compound
annual growth rate (CAGR) of 7.5% from 2024 to 2032. This growth is
fueled by the rising prevalence of chronic diseases like diabetes,
an aging population, and advancements in wound care
technologies.
"Our patenting strategy for this wound-healing product mirrors
our successful approach with other therapies," said Ilya Lapshin, general counsel for CureLab
Oncology. "By initially filing a provisional patent application in
the USA and subsequently seeking
worldwide protection, we aim to secure comprehensive intellectual
property rights for this groundbreaking innovation."
About Elenagen
CureLab's lead investigational compound is code-named Elenagen,
an experimental DNA therapy that consists of a circular piece of
DNA called a plasmid that includes a gene for a human protein
called p62/SQSTM1. In clinical studies conducted ex-US, Elenagen
demonstrated desirable safety profile and statistically significant
clinical benefit for cancer patients enhancing the anti-cancer
effects of chemotherapy. Experimental results also demonstrate
mitigation of chronic inflammation, anti-aging effects, and
stimulation of an immune response to the tumor.
About CureLab Oncology
CureLab Oncology Inc. is a pre-IPO, clinical-stage biotech
company headquartered in the greater Boston area, Massachusetts. CureLab is dedicated to
advancing new and safer therapeutics for solid tumors and other
oncology and inflammatory indications. To learn more,
visit curelab.com.
Media contact:
Tim
Cox, ZingPR, tim@zingpr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/curelab-oncology-files-patent-application-for-groundbreaking-wound-healing-therapy-302183994.html
SOURCE CureLab Oncology Inc.